Cart
sales@molnova.com
Abemaciclib metabolite M20
CAS No. 2138499-06-4
Abemaciclib metabolite M20 ( CDK4/6-IN-4; LSN3106726 )
Catalog No. M26100 CAS No. 2138499-06-4
Abemaciclib metabolite M20 is an active metabolite of Abemaciclib.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 258 | Get Quote |
|
| 10MG | 410 | Get Quote |
|
| 25MG | 678 | Get Quote |
|
| 50MG | 954 | Get Quote |
|
| 100MG | 1287 | Get Quote |
|
| 500MG | 2574 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameAbemaciclib metabolite M20
-
NoteResearch use only, not for human use.
-
Brief DescriptionAbemaciclib metabolite M20 is an active metabolite of Abemaciclib.
-
DescriptionAbemaciclib metabolite M20 is an active metabolite of Abemaciclib. Abemaciclib metabolite M20 is a selective CDK4/6 inhibitor and can be used for researches on the treatment of cancer.
-
SynonymsCDK4/6-IN-4; LSN3106726
-
PathwayAngiogenesis
-
TargetCDK
-
RecptorPEGs
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2138499-06-4
-
Formula Weight522.6
-
Molecular FormulaC27H32F2N8O
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(CO)n(C(C)C)c4c3)nc2)CC1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562.
molnova catalog
related products
-
SU-9516
SU9516 is a selectively potent ATP-competitive inhibitor of CDKs.
-
Roniciclib
A novel potent, orally active, pan-CDK inhibitor with IC50 of 7/9/11 nM for CDK1/2/4 respectively, inhibits transcriptional CDK9/7 with IC50 of 5-25 nM.
-
ML141
ML141 is a potent, selective and reversible non-competitive inhibitor of Rho family GTPase cdc42 with IC50 of 200 nM.
